Ep192: Kate Haviland on Following the Science to Precision Immunology

Episode Summary

Executive Summary: Kate Haviland traces her path from small-town upstate New York to CEO of Blueprint Medicines, showing how a science-plus-business background, deliberate succession planning, and disciplined execution helped turn a kinase-inhibitor oncology company into a commercial immunology success. The key inflection was recognizing avapritinib’s value in systemic mastocytosis, especially indolent SM, and building the clinical, diagnostic, and commercial infrastructure to support it before Sanofi’s $9.1B acquisition.

Main Topics: Early life, education, and discovering her fit (Priority: 5/5): Haviland grew up in Glens Falls, New York in a tight-knit family and originally aimed to become a physician-scientist, inspired by MD-PhD uncles. At Wesleyan, she found bench research less energizing than collaborative, fast-moving work and pivoted toward combining science with economics/business. Consulting and the value of financial fluency (Priority: 4/5): Her early career at Charles River Associates and PA Consulting gave her a crash course in financial analysis, valuation, and strategy. She learned how to translate technical and commercial considerations into a balanced business view, a skill that later became central in biotech operating roles. Genzyme, PTC, and Sarepta: building operating experience (Priority: 5/5): At Genzyme she learned patient-first culture, leadership, and cross-functional decision-making. At PTC and Sarepta she broadened into commercial planning, investor relations, and pre-commercialization, building the operating toolkit needed for a senior biotech leadership role. Joining Blueprint Medicines and the power of platform strategy (Priority: 5/5): Haviland joined Blueprint in 2016 as chief business officer just after the first IND, attracted by the company’s kinase-focused discovery engine, scientific optionality, and intentional culture-building. She explains how commercial thinking early in development can shape trial design, CMC, and future label opportunity. The avapritinib pivot from oncology to immunology (Priority: 5/5): Blueprint initially pursued rare genetically defined cancers, but clinical data showed avapritinib could work at lower doses in systemic mastocytosis. The company invested in understanding advanced and indolent SM, developing diagnostic tools, patient-reported outcomes, and physician/patient education to unlock a much larger chronic-disease market. Leadership transition, culture, and succession planning (Priority: 4/5): Jeff Albers’s move from CEO to executive chair in 2022 reflected a multi-year succession process, with Haviland promoted to CEO and other leaders also advancing. She emphasizes that Blueprint’s success came from a culture of teamwork, resilience, and willingness to pivot as the science evolved. Sanofi acquisition and strategic fit (Priority: 4/5): Blueprint’s launch momentum, broader mast-cell biology opportunity, and pipeline asset Blue-808 helped make the company attractive to Sanofi. Haviland frames the deal as the outcome of a growing commercial asset plus a pipeline and platform that could support bigger global ambitions than a small company could pursue alone.

Key Arguments: A career in biotech benefits from being bilingual in science and economics; Haviland’s pivot into economics made her better at evaluating assets, strategy, and business tradeoffs. Consulting can be an effective gateway into biotech because it builds analytical rigor, finance skills, and exposure to many business problems, even if it is not the final destination. The best biotech companies combine strong science with intentional culture; execution, teamwork, and resilience are as important as the underlying biology. Early commercial perspective matters in development because trial design, dosing, manufacturing, and patient segmentation determine future label and market success. Blueprint’s opportunity expanded when avapritinib proved potent enough at low doses to treat indolent systemic mastocytosis, a chronic inflammatory disease not originally in the plan. Understanding rare disease communities directly—through KOLs, patient groups, and advocacy—can reveal true unmet need and uncover larger-than-expected markets. Succession planning should be deliberate and multi-year; Blueprint’s leadership transition worked because roles were prepared in advance and the board aligned with company timing. A platform company with a validated discovery engine can create optionality, enabling both internal pipeline growth and strategic interest from large pharma. The Sanofi deal reflected not just one drug, but a broader commercial franchise in mast-cell biology plus future opportunities such as Blue-808.

Data Points: Blueprint acquisition value: $9.1 billion cash at closing; up to $9.5 billion with milestones - Sanofi’s acquisition of Blueprint Medicines Haviland’s hometown population: ~50,000 - Glens Falls, New York, where she grew up High school class size: ~200 students - Her graduating class in Glens Falls Wesleyan graduation year: 1998 - She graduated and entered consulting Charles River Associates tenure: 1998-2000 - First job after college HBS enrollment/graduation: 2003-2005 - She attended full-time to pivot into operating biotech roles PTC Therapeutics tenure: 6 years - She moved from consulting into biotech operations Sarepta/Avi stock move: $0.60 to $11-$12 per share - During the relaunch of AVI Biopharma/Sarepta around 2012 Blueprint founding year: 2011 - Company origin Blueprint first IND filed: ~1.5 to 2 months before Jan 2016 - At the time Haviland joined as chief business officer Avapritinib first approval date: January 2020 - First Blueprint approval GIST patient population: ~250 patients in the U.S. - PDGFR-alpha-driven GIST subgroup initially approved Avapritinib annual price: ~$350,000-$400,000 per year - Price for the rare GIST indication Advanced systemic mastocytosis share: 5%-10% of systemic mastocytosis - Advanced form of the disease Systemic mastocytosis patient count: ~2,000-2,500 in the U.S. - Estimated advanced SM population Indolent systemic mastocytosis share: 90%-95% of systemic mastocytosis - Larger chronic-disease opportunity Estimated total SM patients in U.S.: ~60,000 - Broader market estimate cited for systemic mastocytosis Example of severe disease burden: 100 Epipens in one year - A patient in a clinical trial with frequent anaphylaxis Advanced SM prognosis: ~6 months to live - Described for the most aggressive form Avapritinib response rates: ~75%-80%+ - Clinical results described across settings Time from first-in-human to approval: 3 years for one program; 3.5 years for another - Blueprint’s fast development timelines Blueprint commercial growth metric: New prescribers, new patient starts, high persistence/compliance - Indicators of successful launch trajectory

Pivotal Quotes: "We need people who love science and medicine, but who also can be, let's just call it bilingual in terms of thinking through economics or business aspects of science and medicine." — Kate Haviland: A professor’s advice at Wesleyan that changed her career direction "Culture eats strategy for breakfast." — Kate Haviland: Her summary of why people and team dynamics mattered as much as science at Blueprint "If you had told me when I joined Blueprint at the end of 2015, early 2016, that we'd be selling to allergy immunology and dermatology, I would have said you're crazy." — Kate Haviland: Reflecting on Blueprint’s unexpected pivot beyond its original oncology focus

Implications: Biotech success often comes from staying open to unexpected biology, investing early in market understanding, and building a culture that can pivot. Blueprint’s story suggests platform companies can create outsized value when they pair science with disciplined commercial execution.